What is Harpoon Therapeutics, Inc. (HARP)?

Harpoon Therapeutics, Inc. (HARP) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of HARP?

The current price of HARP is $23.01. Prices are updated in real time on Stocks360.

What is HARP's price-to-earnings (PE) ratio?

HARP's trailing twelve-month PE ratio is -1.14, based on current price and earnings per share data available on Stocks360.

What is HARP's market capitalization?

HARP's market capitalization is $865,079,358.00, placing it in the small-cap tier.

Harpoon Therapeutics, Inc. (HARP)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$23.01

Market Cap

$865.08M

PE (TTM)

-1.14

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.55

Day Range

$22.99 – $23.02

52-wk Range

$3.11 – $23.21

Avg Volume

N/A

Volume

6.40M

Harpoon Therapeutics, Inc. (HARP) is a publicly traded company in the Healthcare sector. Latest price: $23.01. Market cap $865.08M. Trailing PE -1.14. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Mar 25, 2024

EPS $-5.50 vs est. $-0.50

Missed by $5.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About Harpoon Therapeutics, Inc.

Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators. These therapies are designed to leverage the body's own immune system to fight cancer and other diseases in patients across the United States. The company's innovative Tri-specific T cell activating construct (TriTAC) platform forms the basis of its development pipeline. This includes HPN328, currently undergoing Phase I/II clinical trials for small cell lung cancer and tumors that express Delta-like canonical Notch ligand 3; HPN217, also in Phase I/II trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical evaluation for ovarian and pancreatic cancers, alongside other mesothelin-expressing tumors. Furthermore, Harpoon has a preclinical asset, HPN601, aimed at various solid tumor indications. The company has also established a discovery collaboration and licensing agreement with AbbVie Biotechnology Ltd. to develop and market products combining its unique TriTAC technology with soluble T cell receptors. Founded in 2015, Harpoon Therapeutics, Inc. is headquartered in South San Francisco, Californi…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-1.14×
P/S (TTM)	27.11×
P/B	14.14×
P/FCF (TTM)	-9.66×
EV / EBITDA	-12.57×
EV / Sales	25.99×
Earnings Yield	-87.97%
Free Cash Flow Yield	-10.35%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$829.47M
Revenue (TTM)	$31.91M
Net Income (TTM)	-$761.01M
Free Cash Flow (TTM)	-$89.53M
Net Debt	-$35.61M
Working Capital	$2.29M
Gross Margin	90.30%
Operating Margin	-214.08%
Net Margin	-210.36%
Return on Equity	-211.56%
Return on Invested Capital	-285.53%